FDA under Makary will accelerate rare disease drug approvals by Q1 20…

Market overview

Makary's tenure has prioritized speeding up drug approvals and clinical trials, particularly for rare diseases. His continued leadership would ensure these initiatives remain a priority, with measurable outcomes visible in public FDA approvals and policy updates by early 2026.

regulatory prediction market

Implied probability (Yes)

75%

More regulatory markets

• UK government increases teacher pay offer by 2%+ in 2027 — 45% Yes
• FIFA issues formal disciplinary action against Trump by 2026-12-31 — 70% Yes
• UK government to allocate £200M for river clean-up by 2026 — 70% Yes
• FIFA issues formal reprimand against U.S. Soccer for Trump interference — 75% Yes
• Trump administration implements AI guardrails by Q4 2026 — 70% Yes
• Senate blocks OMB grant rule by December 2026 — 72% Yes
• Biden administration approves ICE detention project within 6 months — 40% Yes
• Forge Global secures Anthropic approval within 6 months — 75% Yes

Browse all regulatory markets →